Healthy Subjects
Conditions
Brief summary
This study will be a single-center, open-label, randomized, 3-treatment crossover bioavailability study of single oral doses of E5501 old tablet formulation under fasted conditions and a new tablet formulation administered under fed and fasted conditions in healthy subjects.
Interventions
DRUGE5501
Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
Sponsors
Eisai Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Normal healthy adult males and females (age 18-45 years) * Body Mass Index (BMI) greater than or equal to 18 and less than or equal to 32 at the time of Screening * All females must have a negative serum human beta-chorionic gonadotropin test result or negative urine pregnancy test result at Screening and Baseline. Females of child-bearing potential must use a medically acceptable method of contraception throughout the entire study period and for 30 days after study drug discontinuation. Postmenopausal women and women who have been surgically sterilized or are proven sterile are exempt from this requirement. All women who are of reproductive potential and who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation. * Male subjects who are not abstinent or have not undergone a successful vasectomy, who are partners of women of child-bearing potential must use, or their partners must use, a highly effective,method of contraception starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days after the last dose of study drug. * Willing and able to comply with all aspects of the protocol * Provide written informed consent
Exclusion criteria
* Standard selection criteria typically used in all protocols * Clinically significant abnormal laboratory test results, including platelet count and electrolyte abnormalities at Screening and at each Baseline
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the bioavailability (BA) of E5501 in one 40 mg new tablet formulation relative to two 20 mg old tablet formulation. | 2 months |
Secondary
| Measure | Time frame |
|---|---|
| To determine the effect of a high fat meal on the BA of E5501 in one 40 mg new tablet formulation | 2 months |
| To evaluate the safety of E5501 in healthy subjects. | 2 months |
Countries
United States
Outcome results
None listed